News and Press Releases
Press releases
Theralase’s® Lead Photodynamic Compound TLD-1433 Provides New Opportunities in Targeted Cancer Therapy
Press ReleaseTheralase® Researchers Invited to Present at International Conference in Germany Toronto, Ontario – September 4, 2018 Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage phar...
Theralase® Announces Proposed Non-Brokered Private Placement of up to $10 Million
Press ReleaseNot for distribution to U.S. news wire services or dissemination in the United States. Toronto, Ontario – August 28, 2018 Theralase Technologies Inc. (the “Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage p...
Theralase® Provides Corporate Update
Press ReleaseTheralase® Provides Update on Upcoming Initiatives for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study Toronto, Ontario – August 27, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTC...
Theralase® Submits Phase II Bladder Cancer Clinical Study Application to Health Canada for Review and Approval
Press ReleaseToronto, Ontario – August 20, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Ph...
Theralase® Achieves Exploratory Efficacy Endpoint in Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study for Patients Five and Six
Press ReleasePatient Five and Six Demonstrate No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Company Successfully Completes 180 days Follow Up of the Phase Ib Study and Plans Regulatory Filings to Commence a Phase II Clinical Study that...
Theralase® Releases 2Q2018 Financial Statements
Press ReleaseToronto, Ontario – July 26, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Demonstrates Anti-Cancer Technology Prevents Recurrence of Bladder Cancer at 180 Days Post-Treatment
Press ReleasePatient Five Demonstrates No Clinical Evidence of NMIBC at 180 Day Cystoscopy Analysis Toronto, Ontario – July 16, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage p...
Theralase® Releases AGM Videos
Press ReleaseToronto, Ontario – June 29, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Phot...
Theralase® Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin® Based Photo Dynamic Therapy, in Immune Privileged Sites
Press ReleaseToronto, Ontario – June 22, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase® Demonstrates Significant Advantage in Treatment of Brain Tumours
Press ReleaseToronto, Ontario – June 11, 2018, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activat...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
